Strongbridge Biopharma plc (SBBP)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NSADAQ: SBBP).  The investigation concerns whether Strongbridge and certain of its officers and/or directors have violated federal securities laws.

 

On September 8, 2020, Strongbridge issued a press release entitled “Strongbridge Biopharma’s Recorlev successful in Cushing’s syndrome study.”  While the press release touted “positive results from [Strongbridge’s] 44-subject Phase 3 clinical trial, LOGIC, evaluating Recorlev (levoketoconazole) in patients with endogenous Cushing’s syndrome,” the press release also disclosed treatment-emergent adverse events” that included “nausea (29%), hypokalemia (28%), headache (21%), hypertension (19%) and diarrhea (15%).”  On this news, Strongbridge’s stock price fell $0.71 per share, or 20.11%, to close at $2.82 per share on September 8, 2020.

 

If you are aware of any facts relating to this investigation, or purchased Strongbridge shares,  you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.